Carlyle, H&F Ponder Partial Sale Of PPD At $9B+ Valuation

0
Carlyle, H&F Ponder Partial Sale Of PPD At $9B+ Valuation
By The Carlyle Group (annual report),User:Fairlyoddparents1234 (uploaded result) [Public domain], via Wikimedia Commons

The Carlyle Group and Hellman & Friedman have entered into “advanced talks” to sell minority stakes in Pharmaceutical Product Development to investors including sovereign wealth funds GIC and the Abu Dhabi Investment Authority, according to Reuters. The deal would value the North Carolina-based clinical trial provider at more than $9 billion, including debt.

Play Quizzes 4

Though the deal structure is unknown, Carlyle and H&F, which currently own 60% and 40% of the company, respectively, would still combine to retain a majority stake.

Maverick Capital Slides 22.9% In Q1, Short Bets Yield Positive Returns [Exclusive]

investor 1652197064Maverick Capital's flagship hedge fund lost -22.9% in the first quarter of 2022 according to a copy of the firm's quarterly update, which ValueWalk has been able to review. The firm's flagship fund, Maverick Fundamental Hedge, accounts for $3.7 billion of the group's $8.1 billion of assets under management. Even after losses in the first Read More

The news comes after the firms fielded an offer for PPD from Pamplona Capital Management earlier this month, per the report. But Pamplona, despite additional backing from LetterOne, didn’t value the company as highly as latest rumored offer.

If the new deal goes through, it would likely represent a hefty return for Carlyle and H&F, which acquired PPD for $3.9 billion in a take-private transaction in 2011.

On a broader scale, PE investment in the US healthcare services industry is off to a slow start in 2017, with just 68 completed deals so far, according to the PitchBook Platform. If that pace continues, it would mark a steep decline from the decade-high 428 transactions in the sector last year and set a low mark since 2013.

PitchBook Platform users can view the full dataset here.

Article by Adam Lewis, PitchBook

Updated on

No posts to display